Alkem Laboratories launches Brivasure

15 Mar 2021 Evaluate

Alkem Laboratories (Alkem) has launched Brivasure, an affordable anti-epileptic drug for the treatment of Epilepsy in India. Brivasure, Alkem’s anti-epileptic drug (AED) is a generic version of the parent molecule. Alkem has launched the drug in the market at price, Brivasure 25mg - Rs.79.50/strip, Brivasure 50mg - Rs. 148.50/strip, Brivasure 75mg - Rs. 230/strip, Brivasure 100mg - Rs. 295/strip, post patent expiry of innovator product, of Brivaracetam as on February 21, 2021.

The drug has been approved by the Drugs Controller General of India (DCGI) in the adjunctive management of partial onset seizure with or without secondary generalization. The drug has exhibited faster onset of action, efficacy with favorable safety profile.

Alkem Laboratories is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical Ingredients (APIs) and nutraceuticals, which it markets in India and International markets.

Alkem Laboratories Share Price

4906.35 -92.65 (-1.85%)
28-Mar-2024 15:31 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1631.40
Dr. Reddys Lab 6171.85
Cipla 1497.55
Zydus Lifesciences 1013.75
Lupin 1617.80
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.